SCHEMBL1500258

SCHEMBL1500258

CC(CN1Cc2cc(Br)ccc2C1=O)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SDCBP O00560 6/20 0.52
SDC2 P34741 6/20 0.52
PRMT5 O14744 4/20 0.45
WDR77 Q9BQA1 4/20 0.45
DPP8 Q6V1X1 1/20 0.41
DPP9 Q86TI2 1/20 0.41
DPP7 Q9UHL4 1/20 0.41
ITGAV P06756 1/20 0.40
LMNA P02545 2/20 0.39
PMP22 Q01453 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GFER P55789 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
SIRT1 Q96EB6 1/20 0.38
SRD5A1 P18405 1/20 0.38
SRD5A2 P31213 1/20 0.38
DNMT1 P26358 1/20 0.38
APAF1 O14727 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15795942 0.85 PRMT5 (0.50) SDCBPSDC2PRMT5WDR77DPP8
SCHEMBL1500223 0.85 PRMT5 (0.46) SDCBPSDC2PRMT5WDR77DPP8
SCHEMBL15939257 0.79 ITGB3 (0.50) SDCBPSDC2PRMT5WDR77KDM4E
SCHEMBL1027654 0.79 PRMT5 (0.46) SDCBPSDC2PRMT5WDR77
SCHEMBL27080051 0.78 PRMT5 (0.44) SDCBPSDC2PRMT5WDR77SRD5A1
SCHEMBL1500695 0.78 CUL4A (0.49) SDCBPSDC2PRMT5WDR77KDM4E
SCHEMBL1029578 0.77 HSD17B3 (0.49) SDCBPSDC2PRMT5WDR77SRD5A1
SCHEMBL2177896 0.77 SDCBP (0.65) SDCBPSDC2KDM4EALOX15TSHR
SCHEMBL2177628 0.76 SDCBP (0.61) SDCBPSDC2LMNAKDM4EALOX15
SCHEMBL27034429 0.76 KDM4E (0.41) SDCBPSDC2PRMT5WDR77ITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160208-A1 DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-30 US disclosed
US-7902369-B2 Diaryl-substituted five-membered heterocycle derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-20070173507-A1 Dairyl-substituted five-membered heterocycle derivative MSD K.K. (JP) 2007-07-26 US disclosed
EP-1726585-A1 DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160208-A1 DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE OPRK1, GRM1, GRIK1 SDCBP 2018/4885SDC2 2553/4885PRMT5 2310/4885
US-20070173507-A1 Dairyl-substituted five-membered heterocycle derivative OPRK1, OPRL1, GRM1 SDCBP 1614/4885SDC2 2393/4885PRMT5 2773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.